Immuron (IMRN) Net Income towards Common Stockholders (2016 - 2024)

Immuron (IMRN) recorded quarterly Net Income towards Common Stockholders of $1660259165.7 billion in Q4 2024, up 80082653894884.78% quarter-over-quarter from -$2.1 million in Q4 2023, and up 80082653894884.8% on a YoY basis from N/an in Q1 2024.

Immuron (IMRN) Net Income towards Common Stockholders (2016 - 2024) Analysis & Trends

Immuron's Net Income towards Common Stockholders history runs 9 years deep, the most recent figure standing at $1660259165.7 billion for Q4 2024.

  • In Q4 2024, Net Income towards Common Stockholders rose 80082653894884.8% year-over-year to $1660259165.7 billion; the TTM figure through Sep 2025 stood at $1660259165.7 billion (up 470814844753249.8% YoY), while the FY2025 annual figure was -$3.4 million, up 25.69% from the prior year.
  • Net Income towards Common Stockholders was $1660259165.7 billion for Q4 2024 at Immuron, up from -$2.1 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $1660259165.7 billion in Q4 2024 to a low of -$2.1 million in Q4 2023.
  • Historically, Net Income towards Common Stockholders has averaged $237179880.8 billion across 5 years, with a median of -$13260.2 in 2021.
  • The sharpest annual moves came in 2020 and 2024: Net Income towards Common Stockholders plunged 277.25% in 2020, then jumped 80082653894884.8% in 2024.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$57387.7 in 2020, then soared by 76.89% to -$13260.2 in 2021, then surged by 13879.86% to $1.8 million in 2022, then sank by 213.46% to -$2.1 million in 2023, then surged by 80082653894884.78% to $1660259165.7 billion in 2024.
  • The last three Net Income towards Common Stockholders figures came in at $1660259165.7 billion (Q4 2024), -$2.1 million (Q4 2023), and $2.4 million (Q3 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -26.94 Mn
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -13.56 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 2.50 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -3.63 Mn
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -14.46 Mn
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -1.50 Mn
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 1.03 Bn
9 Abivax 91.96 Bn 91.96 Bn - -56.48 Mn
10 Immuron 921.61 Mn 921.58 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2024 1,660,259,165.67 Bn
Dec 31, 2023 -2.07 Mn
Sep 28, 2023 2.43 Mn
Jun 30, 2023 -1.24 Mn
Dec 31, 2022 1.83 Mn
Dec 31, 2021 -13,260.17
Dec 31, 2020 -57,387.72
Dec 31, 2019 -15,212.27
Dec 31, 2018 -1.58 Mn
Dec 31, 2017 3.84 Mn
Dec 31, 2016 2.56 Mn
Jun 30, 2016 -3.28 Mn